Adlai Nortye Group Ltd. is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies, particularly in the field of immuno-oncology. The company's business model centers on the discovery, development, and eventual commercialization of targeted treatments for various tumor types. Its pipeline includes multiple preclinical and clinical-stage drug candidates, such as AN2025 (buparlisib), a pan-PI3K inhibitor in late-stage trials for head and neck cancer, and AN0025, an EP4 antagonist. Adlai Nortye leverages a dual R&D and operational footprint, with regional headquarters and laboratories in Hangzhou, China, and North Brunswick, New Jersey, USA. The company collaborates with major multinational pharmaceutical firms, including Novartis and Merck, to advance its clinical programs. As a pre-revenue, clinical-stage company, it does not yet generate commercial product sales and relies on funding from equity offerings and partnerships to support its extensive research and development activities.
